Literature DB >> 24943274

Engineered T cells for cancer therapy.

Carl H June1, Marcela V Maus, Gabriela Plesa, Laura A Johnson, Yangbing Zhao, Bruce L Levine, Stephan A Grupp, David L Porter.   

Abstract

It is now well established that the immune system can control and eliminate cancer cells. Adoptive T cell transfer has the potential to overcome the significant limitations associated with vaccine-based strategies in patients who are often immune compromised. Application of the emerging discipline of synthetic biology to cancer, which combines elements of genetic engineering and molecular biology to create new biological structures with enhanced functionalities, is the subject of this focused research review.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24943274      PMCID： PMC4142345          DOI： 10.1007/s00262-014-1568-1

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN： 0340-7004            Impact factor:   6.968


  54 in total

Review 1.  Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance.

Authors:  F M Marincola; E M Jaffee; D J Hicklin; S Ferrone
Journal:  Adv Immunol       Date:  2000       Impact factor: 3.543

2.  Cancer regression in patients after transfer of genetically engineered lymphocytes.

Authors:  Richard A Morgan; Mark E Dudley; John R Wunderlich; Marybeth S Hughes; James C Yang; Richard M Sherry; Richard E Royal; Suzanne L Topalian; Udai S Kammula; Nicholas P Restifo; Zhili Zheng; Azam Nahvi; Christiaan R de Vries; Linda J Rogers-Freezer; Sharon A Mavroukakis; Steven A Rosenberg
Journal:  Science       Date:  2006-08-31       Impact factor: 47.728

Review 3.  T cells as a self-referential, sensory organ.

Authors:  Mark M Davis; Michelle Krogsgaard; Morgan Huse; Johannes Huppa; Bjoern F Lillemeier; Qi-jing Li
Journal:  Annu Rev Immunol       Date:  2007       Impact factor: 28.527

4.  Perspective: assembly line immunotherapy.

Authors:  Bruce L Levine; Carl H June
Journal:  Nature       Date:  2013-06-27       Impact factor: 49.962

5.  Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product.

Authors:  H M Finney; A D Lawson; C R Bebbington; A N Weir
Journal:  J Immunol       Date:  1998-09-15       Impact factor: 5.422

6.  T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells.

Authors:  Juan Vera; Barbara Savoldo; Stephane Vigouroux; Ettore Biagi; Martin Pule; Claudia Rossig; Jessie Wu; Helen E Heslop; Cliona M Rooney; Malcolm K Brenner; Gianpietro Dotti
Journal:  Blood       Date:  2006-08-22       Impact factor: 22.113

7.  Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

Authors:  James N Kochenderfer; Wyndham H Wilson; John E Janik; Mark E Dudley; Maryalice Stetler-Stevenson; Steven A Feldman; Irina Maric; Mark Raffeld; Debbie-Ann N Nathan; Brock J Lanier; Richard A Morgan; Steven A Rosenberg
Journal:  Blood       Date:  2010-07-28       Impact factor: 22.113

8.  Early diagnostic and prognostic significance of a specific Th1/Th2 cytokine pattern in children with haemophagocytic syndrome.

Authors:  Yongmin Tang; Xiaojun Xu; Hua Song; Shilong Yang; Shuwen Shi; Jian Wei; Binhua Pan; Fenying Zhao; Chan Liao; Chunfang Luo
Journal:  Br J Haematol       Date:  2008-07-31       Impact factor: 6.998

9.  Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.

Authors:  Richard A Morgan; Nachimuthu Chinnasamy; Daniel Abate-Daga; Alena Gros; Paul F Robbins; Zhili Zheng; Mark E Dudley; Steven A Feldman; James C Yang; Richard M Sherry; Giao Q Phan; Marybeth S Hughes; Udai S Kammula; Akemi D Miller; Crystal J Hessman; Ashley A Stewart; Nicholas P Restifo; Martha M Quezado; Meghna Alimchandani; Avi Z Rosenberg; Avindra Nath; Tongguang Wang; Bibiana Bielekova; Simone C Wuest; Nirmala Akula; Francis J McMahon; Susanne Wilde; Barbara Mosetter; Dolores J Schendel; Carolyn M Laurencot; Steven A Rosenberg
Journal:  J Immunother       Date:  2013-02       Impact factor: 4.456

10.  Blockade of TGF-β signaling greatly enhances the efficacy of TCR gene therapy of cancer.

Authors:  Gavin M Bendle; Carsten Linnemann; Laura Bies; Ji-Ying Song; Ton N M Schumacher
Journal:  J Immunol       Date:  2013-08-12       Impact factor: 5.422
View more
  46 in total

1.  Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer.

Authors:  Edmund K Moon; Raghuveer Ranganathan; Evgeniy Eruslanov; Soyeon Kim; Kheng Newick; Shaun O'Brien; Albert Lo; Xiaojun Liu; Yangbing Zhao; Steven M Albelda
Journal:  Clin Cancer Res       Date:  2015-08-31       Impact factor: 12.531

Review 2.  Are CAR T cells better than antibody or HCT therapy in B-ALL?

Authors:  Michael A Pulsipher
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

3.  A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab.

Authors:  Theodore S Nowicki; Beata Berent-Maoz; Gardenia Cheung-Lau; Rong Rong Huang; Xiaoyan Wang; Jennifer Tsoi; Paula Kaplan-Lefko; Paula Cabrera; Justin Tran; Jia Pang; Mignonette Macabali; Ivan Perez Garcilazo; Ignacio Baselga Carretero; Anusha Kalbasi; Alistair J Cochran; Catherine S Grasso; Siwen Hu-Lieskovan; Bartosz Chmielowski; Begoña Comin-Anduix; Arun Singh; Antoni Ribas
Journal:  Clin Cancer Res       Date:  2018-12-20       Impact factor: 12.531

4.  Antioxidant metabolism regulates CD8+ T memory stem cell formation and antitumor immunity.

Authors:  Karolina Pilipow; Eloise Scamardella; Simone Puccio; Sanjivan Gautam; Federica De Paoli; Emilia Mc Mazza; Gabriele De Simone; Sara Polletti; Marta Buccilli; Veronica Zanon; Pietro Di Lucia; Matteo Iannacone; Luca Gattinoni; Enrico Lugli
Journal:  JCI Insight       Date:  2018-09-20

5.  Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies.

Authors:  David T Rodgers; Magdalena Mazagova; Eric N Hampton; Yu Cao; Nitya S Ramadoss; Ian R Hardy; Andrew Schulman; Juanjuan Du; Feng Wang; Oded Singer; Jennifer Ma; Vanessa Nunez; Jiayin Shen; Ashley K Woods; Timothy M Wright; Peter G Schultz; Chan Hyuk Kim; Travis S Young
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-12       Impact factor: 11.205

Review 6.  CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia.

Authors:  Shannon L Maude; David T Teachey; David L Porter; Stephan A Grupp
Journal:  Blood       Date:  2015-05-21       Impact factor: 22.113

7.  CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia.

Authors:  Challice L Bonifant; Arpad Szoor; David Torres; Nicholos Joseph; Mireya Paulina Velasquez; Kota Iwahori; Amos Gaikwad; Phuong Nguyen; Caroline Arber; Xiao-Tong Song; Michele Redell; Stephen Gottschalk
Journal:  Mol Ther       Date:  2016-06-06       Impact factor: 11.454

Review 8.  Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You.

Authors:  Marco Ruella; Carl H June
Journal:  Curr Hematol Malig Rep       Date:  2016-10       Impact factor: 3.952

9.  Time to Akt: Superior tumor-reactive T cells for adoptive immunotherapy.

Authors:  Anniek B van der Waart; Willemijn Hobo; Harry Dolstra
Journal:  Oncoimmunology       Date:  2015-02-03       Impact factor: 8.110

Review 10.  Strategies to genetically engineer T cells for cancer immunotherapy.

Authors:  Timothy T Spear; Kaoru Nagato; Michael I Nishimura
Journal:  Cancer Immunol Immunother       Date:  2016-05-02       Impact factor: 6.968
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.